For patients diagnosed with stage 4 cancer, a condition often accompanied by limited treatment options and grim prognoses, immunotherapy offers a new ray of hope. This groundbreaking approach utilizes ...
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma We conducted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback